Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.
about
Epigenetic modulators, modifiers and mediators in cancer aetiology and progressionHistone methyltransferases: novel targets for tumor and developmental defectsProgress in epigenetic histone modification analysis by mass spectrometry for clinical investigationsThe interplay of histone modifications - writers that readMutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomasProteomics-based discovery of biomarkers for paediatric acute lymphoblastic leukaemia: challenges and opportunitiesRedefining ALL classification: toward detecting high-risk ALL and implementing precision medicineStructural variation discovery in the cancer genome using next generation sequencing: computational solutions and perspectivesGain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic interventionQuantitative proteomic analysis of histone modificationsMutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemiaIn vitro clinical trials: the future of cell-based profiling.Childhood B-acute lymphoblastic leukemia: a genetic update.Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapseWolf-Hirschhorn Syndrome Candidate 1 (whsc1) Functions as a Tumor Suppressor by Governing Cell Differentiation.Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylationStable-isotope-labeled histone peptide library for histone post-translational modification and variant quantification by mass spectrometryThe landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes.Chemical profiling of the genome with anti-cancer drugs defines target specificities.Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation.Developmental control of polycomb subunit composition by GATA factors mediates a switch to non-canonical functions.Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.Mutational spectrum of adult T-ALLFunctional Proteomic Analysis of Repressive Histone Methyltransferase Complexes Reveals ZNF518B as a G9A Regulator.Large-Scale Targeted Proteomics Using Internal Standard Triggered-Parallel Reaction Monitoring (IS-PRM).Pathology Tissue-quantitative Mass Spectrometry Analysis to Profile Histone Post-translational Modification Patterns in Patient Samples.Reduced-representation Phosphosignatures Measured by Quantitative Targeted MS Capture Cellular States and Enable Large-scale Comparison of Drug-induced PhenotypesLarge-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma.Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL).Targeting EZH2 and PRC2 dependence as novel anticancer therapy.A Multiplexed System for Quantitative Comparisons of Chromatin Landscapes.Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression.A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin.Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.Epigenetics of hematopoiesis and hematological malignancies.Mutated Chromatin Regulatory Factors as Tumor Drivers in CancerDevelopment of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples.Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach.The Role of Histone Protein Modifications and Mutations in Histone Modifiers in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia.
P2860
Q26766149-72B856DB-10A9-4429-ABB0-8E83D1D1B2EAQ26775027-E9207587-505F-48CB-9FE8-3983B6A0042EQ26781745-B4553136-7C74-4F7F-B5B2-0E0C39214BBFQ26782196-43066EC2-BC22-448C-8B36-E155DAA2E452Q26782506-9B0A3C7C-99EF-48D1-9AD0-B751345897D1Q26861489-4C326C52-58B6-4E41-B873-F079A86A6CADQ26864460-F306D5F9-122F-4FA8-9F1B-9675EF64FFA9Q26991436-7095D731-7A2B-4E7C-AAE9-DAB59AF1F8BCQ27024233-C3B437AE-DC0C-41FE-8970-14A4E5BF4CF9Q30375585-F2251099-433C-4BA7-9C48-39C0B18704D7Q33594629-7B01E753-8A07-4F76-851A-419D14A0FBA0Q33676812-40B01509-66F7-4B47-964D-B11BDEA7A91EQ33777616-4CEAD349-F20C-4A1C-97C9-57299627FA6EQ33798890-AB53184D-5702-40F3-A06D-2815C5F2DE7AQ33842762-1A8CEF7E-7E5B-4ABB-8A1F-898F0E913A6EQ34133622-53D656A7-DE50-4F54-B06F-3279E1E65AB2Q34157702-ABE98943-2005-4E9C-9221-7A2899FC7D19Q34414087-985BA279-ACF9-4BEF-9E31-F4AC114CEDF8Q34475915-761A6961-3C70-40EC-B2B7-E1BE43671141Q34490429-CAAD755F-3BA5-48A8-8FC0-B6D4A0A95EEEQ35007905-E61C10A0-DC62-44CC-AC04-A600C0E75AA6Q35227439-A6C35988-877A-4C0A-83B2-B915962788EAQ35550090-E54C3895-18CC-4685-A3B2-59FFF6793B0DQ35692081-8CA11369-F73E-4D03-B05D-DA0E2E7608FEQ35692132-B8EC1FE9-9E87-464A-B139-9999ECAD387FQ35805423-0E1C4602-38F1-4D69-A80C-DEADA835E6BEQ35935148-48AEE3A3-3298-4AA7-A889-0F027DA800ACQ36040373-9BA22342-FED5-4780-B351-65E1D34F52BDQ36243352-44C056B4-FB80-4421-9B35-AFBE046EAD70Q36445523-B8A2ADA8-8B3D-4CEE-A378-116DE6966AC0Q36450242-5DE7646A-1094-4AFE-8EB7-69F3C4E4247CQ36745131-7E2ED482-B56B-4D89-AB75-C23E663698E4Q36884617-E269117A-CF1A-4231-93FA-F689CEEA935AQ36956610-71A878E3-36B8-4832-9D4A-9E2828455C2AQ37240015-42F5D341-7DEB-4162-A9CA-CAB57E63987CQ37343797-6AD6B606-4201-4571-8F33-4F459A88C86EQ37592666-C82E2836-7271-4E48-9FDC-280CA2E37B05Q37619708-CA7EA9A5-F8DE-46B9-ACD5-34960C00BC23Q37623655-F3810D3C-030D-417B-8C4D-6236E53BD3C3Q37629537-262A8E33-2AD9-49E0-8D0B-E08645048D52
P2860
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Global chromatin profiling rev ...... acute lymphoblastic leukemia.
@ast
Global chromatin profiling rev ...... acute lymphoblastic leukemia.
@en
Global chromatin profiling rev ...... acute lymphoblastic leukemia.
@nl
type
label
Global chromatin profiling rev ...... acute lymphoblastic leukemia.
@ast
Global chromatin profiling rev ...... acute lymphoblastic leukemia.
@en
Global chromatin profiling rev ...... acute lymphoblastic leukemia.
@nl
prefLabel
Global chromatin profiling rev ...... acute lymphoblastic leukemia.
@ast
Global chromatin profiling rev ...... acute lymphoblastic leukemia.
@en
Global chromatin profiling rev ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P50
P356
P1433
P1476
Global chromatin profiling rev ...... acute lymphoblastic leukemia.
@en
P2093
E Robert McDonald
Frank Stegmeier
Giordano Caponigro
Gregory V Kryukov
Ho Man Chan
Hyo-eun C Bhang
Jacob D Jaffe
James R Downing
P2860
P2888
P304
P356
10.1038/NG.2777
P407
P577
2013-09-29T00:00:00Z